The Case CCC is committed to the clinical development of novel concepts through early phase clinical investigation. A long track record of successful translation of 'home-grown'scientific concepts has been facilitated by Protocol Specific Research Support (PSRS), and we continue our focus on investigator initiated, innovative, feasibility and Phase 1 clinical research protocols that contain laboratory correlates to advance the science of therapeutic discovery. PSRS is overseen by the Case CCC Clinical Research Office (CRO), which coordinates the activities of the Clinical Trials Core Facility (CTCF), Protocol Review and Monitoring Committee (PRMC), Data and Safety Monitoring, and Protocol Specific Research Support. The Case CCC has a robust infrastructure for early drug development, with consortium member institutional support in addition to a U01 (Dowlati, PI 5U01CA062502-18, Phase I Emphasis) grant and a NOI (Villalona, Consortium Pl, HHSN261201100070C, Phase 11 Emphasis) NIH contract. Further infrastructure support is enabled by the Case Western Reserve University Clinical Translational Research Collaborative (Davis, Pl 5UL1RR024989-05, CTSC), which provides additional expertise in drug development. While PSRS support explicitly does not overlap with these funding mechanisms, we are able to build upon the extensive local expertise in early phase clinical research in the design and conduct of Cancer Center studies eligible for PSRS. PSRS is limited to support of research nurses and data managers, and therefore leverages other institutional resources. A formalized process for award of PSRS funding begins with the submission of a 2 page letter of intent (LOI) and budget by principal investigators seeking PSRS for a particular study. This LOI undergoes structured evaluation by a Case CCC clinical research leadership committee with a determination of approval/disapproval. PSRS funds are disbursed based on protocol accrual, with per-patient reimbursement at rates determined at the time of approval of the application. Trials must be approved and prioritized by PRMC before any funds are distributed. To permit rapid real-time decision making, PSRS applications are accepted on a rolling basis. In the prior grant cycle, 431 patients were accrued to studies selected for PSRS.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Anderson, Christian E; Wang, Charlie Y; Gu, Yuning et al. (2018) Regularly incremented phase encoding - MR fingerprinting (RIPE-MRF) for enhanced motion artifact suppression in preclinical cartesian MR fingerprinting. Magn Reson Med 79:2176-2182|
|Burger, Denis R; Parker, Yvonne; Guinta, Kathryn et al. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant 24:260-266|
|Shi, Xiaojun; Wang, Bingcheng (2018) Caught in the ""Akt"": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF. Sci Signal 11:|
|Tartakoff, Alan Michael; Dulce, David; Landis, Elizabeth (2018) Delayed Encounter of Parental Genomes Can Lead to Aneuploidy in Saccharomyces cerevisiae. Genetics 208:139-151|
|Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231|
|Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903|
|Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376|
|Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237|
|Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601|
|Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643|
Showing the most recent 10 out of 1227 publications